Where do we go from here: A reflection of COVID-19

In Jan 2020, the sudden emergence of a previously unknown, highly contagious respiratory pathogen launched a global pandemic that remains circulating today. The SARS-CoV-2 coronavirus that causes COVID-19 has surpassed 211 million infections worldwide within twenty months of the pandemic, resulting in more than four million deaths until August 2021 (Coronavirus Resource Center, 2021). Not since 1918 has the world been so affected by the emergence, spread, and death toll resulting from a respiratory virus that impacted on not only global public health but also the economic status of nations and individuals. This devastating public health emergency called for a comprehensive response that required the joint effort of pharmaceutical, biotech, and academic collaborators to develop prevention and treatment approaches for this new disease.

This article is a reflection of COVID-19, following some possible solutions for related research, vaccine and diagnostics development.

• What we have achieved in the fight against COVID-19

• What remains unknown about the virus

• What ACRO offer

ACROBiosystems is dedicated to aid the global COVID-19 response. As a leading life science supplier, we remain steadfast in our mission to support researchers, developers and manufacturers with key reagents to better address the persisting public health concerns. As such, we have consolidated our product and service offerings to a comprehensive solution for SARS-CoV-2, which meet customers' need in both the detection of COVID-19 and the development of vaccines and therapies. As SARS-CoV-2 continues to spread and evolve, our top priority is to provide support to rapidly respond to the challenges. Now, more than ever, we are mobilizing forces to keep the circulating and emerging SARS-CoV-2 variants under surveillance and develop products targeting the Variants of Concerns (VOCs) in the timeliest manner. Our product pipeline includes multiple recombinant antigen mutants, broadly neutralizing antibodies, ELISA kits with high sensitivity and protein-pre-coupled magnetic beads that support high-throughput applications.

We have developed a series of ELISA kits for SARS-CoV-2 detection, including antibody serological titer kits, neutralizing antibody serological titer kits, antigen titer kits, variants inhibitor screening kits, antigen-pre-coated plates, etc.
High sensitivity and specificity.
Can significantly increase your experiment efficiency while ensuring highly reproducible results.
High-throughput, can test 90+ samples in two hours

Produced by coupling biotinylated antigens to streptavidin-conjugated magnetic beads
Pre-coupled & ready to use for capturing target proteins from the sample
Can be used for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity
High yield and low non-specific binding
Suitable for immunocapture, biopanning, flow cytometry, etc.
Cost effective: cut time and human effort during experiment

>>> References

[1] COVID-19 Map, Johns Hopkins Coronavirus Resource Center, 27 Aug 2021. Retrieved from https://coronavirus.jhu.edu  /map.html

[2] WHO Coronavirus (COVID-19) Dashboard with Vaccination Data, World Health Organization, 27 Aug 2021. Retrieved from   https://covid19.who.int/

[3] 7 Vaccines Approved for Use by WHO, COVID-19 Vaccine Tracker. Retrieved from https://covid19.trackvaccines.org  /agency/who/

[4] Scudellari M. How the coronavirus infects cells — and why Delta is so dangerous. Nature (28 July 2021). Retrieved from   https://www.nature.com/articles/d41586-021-02039-y

[5] Andersen, K.G., Rambaut, A., Lipkin, W.I. et al. The proximal origin of SARS-CoV-2. Nat Med 26, 450‒452 (2020).   https://doi.org/10.1038/s41591-020-0820-9